Related Experiment Videos
Looking Beyond Glycaemic Control: Real-World 12-Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5
Eleanor McNally1,2, Iona Goodman1, Rebecca Morris1
1School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Aims:
To evaluate the real-world effectiveness, safety, and tolerability of the Omnipod 5 hybrid closed-loop system in adults with type 1 diabetes (T1D) with a novel focus on cardiometabolic markers alongside diabetic eye disease and renal function.
Methods:
A single-centre, retrospective analysis of adults with T1D using Omnipod 5 was conducted. Case notes were reviewed for routinely collected clinical data. Continuous glucose monitoring (CGM) metrics were obtained from cloud-based platforms at 3, 6 and 12 months. Paired data were analysed with two-tailed t-tests or Wilcoxon signed-rank, with results presented as mean (SD) or median (IQR).
Results:
One hundred individuals were included (63% female). At baseline, median age was 28 (23.0-37.8) years, BMI 27.0 (22.3-30.0) kg/m2, diabetes duration 16.0 (9.0-24.8) years and mean HbA1c 68 (±18.0) mmol/mol. Over half (52%) transitioned from multiple daily injections. Significant glycaemic improvements were observed by 3 months. Improvements were durable to 12 months, with mean HbA1c falling from 68.5 to 58.8 mmol/mol (p < 0.001, n = 75) and time in range (TIR) increasing from 43.4% to 58.3% (p < 0.001, n = 86). The greatest glycaemic improvements were observed in those with lower TIR at baseline. Retinopathy progression occurred in a minority of 10 individuals, all of whom had a baseline HbA1c > 53 mmol/mol.
Conclusions:
Initiation of Omnipod 5 was associated with durable glycaemic improvements. Preliminary data generate the hypothesis that retinopathy progression may be concentrated among individuals with baseline HbA1c above target range. Prospective studies are required to evaluate long-term retinal and cardiometabolic outcomes while controlling for concomitant weight and lipid-lowering therapies.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes III: Clinical Manifestations
Type II Diabetes I: Introduction
Type I Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis